by Lee JSF, Teyssier LS, Nguimfack BD, Collins IJ, Lallemant M, Perriens J and Moatti JP. BMC Pediatrics 2016, 16:41. doi:10.1186/s12887-016-0578-x
Summary: The pediatric antiretroviral (ARV) market is poorly described in the literature, resulting in gaps in understanding treatment access. We analyzed the pediatric ARV market from 2004 to 2012 and assessed pricing trends and associated factors. The study found that the donor funded pediatric ARV market as represented by the Global Price Reporting Mechanism (GPRM) database is small, and lacks price competition. It is dominated by generic drugs due to the lower prices offered and the practicality of fixed dose combination formulations. This market requires continued donor support and the current initiatives to protect it are important to ensure market viability, especially if new formulations are to be introduced in the future.